Breakout From Tight Consolidation Range With Volumes

24 ต.ค. 2024

PPLPHARMA today broke from the Narrow Consolidation Phase. After the previous Breakout in the consolidation phase, letting the 50 EMA Catch up, There Was continuous accumulation, as you can see from the volume intensity in the range. Today, on the back of magnificent Q2 FY 24-25 results, The Stock has blasted to a new All-Time High.

View:

Although the Stock is Overvalued at 588 P/E. Investors Should do Stock SIP or Buy on DIPS and Traders Should Wait for a Retracement to 50 EMA or a Good Consolidation Going Forward.

PPLPHARMA is part of the Piramal group of companies. The company operates through 3 major segments.

1) Contract development and manufacturing organisations (CDMO)
2) Complex hospital generics (critical care)
3) Consumer Healthcare, Over-the-Counter (OTC)

PPLPHARMA entered the Pharma space in 1988 with the acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions and various organic initiatives. In 2010 the Domestic formulations business was sold to About $3.7 billion and Diagnostic Services were sold to Super Religare Laboratories (SRL).

🙋‍♀️🙋‍♂️If you have any questions about this stock, feel free to reach out to me.

📌Thank you for exploring my idea! I hope you found it valuable.

🙏FLLOW for more
👍BOOST if useful
✍️COMMENT Below your views.

Meanwhile, check out my other stock ideas below until this trade is activated. I would love your feedback.

Disclaimer: This analysis is intended solely for informational and educational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.

31 ต.ค. 2024

ปิดการเทรด: ถึงเป้าหมายการทำกำไร

Made new ATH